
via IU School of Medicine
Worldwide, 1 in 4 people will suffer from a depressive episode in their lifetime
While current diagnosis and treatment approaches are largely trial and error, a breakthrough study by Indiana University School of Medicine researchers sheds new light on the biological basis of mood disorders, and offers a promising blood test aimed at a precision medicine approach to treatment.
Led by Alexander B. Niculescu, MD, PhD, Professor of Psychiatry at IU School of Medicine, the study was published today in the high impact journal Molecular Psychiatry. The work builds on previous research conducted by Niculescu and his colleagues into blood biomarkers that track suicidality as well as pain, post-traumatic stress disorder and Alzheimer’s disease.
“We have pioneered the area of precision medicine in psychiatry over the last two decades, particularly over the last 10 years. This study represents a current state-of-the-art outcome of our efforts,” said Niculescu. “This is part of our effort to bring psychiatry from the 19th century into the 21st century. To help it become like other contemporary fields such as oncology. Ultimately, the mission is to save and improve lives.”
The team’s work describes the development of a blood test, composed of RNA biomarkers, that can distinguish how severe a patient’s depression is, the risk of them developing severe depression in the future, and the risk of future bipolar disorder (manic-depressive illness). The test also informs tailored medication choices for patients.
This comprehensive study took place over four years, with over 300 participants recruited primarily from the patient population at the Richard L. Roudebush VA Medical Center in Indianapolis. The team used a careful four-step approach of discovery, prioritization, validation and testing.
First, the participants were followed over time, with researchers observing them in both high and low mood states—each time recording what changed in terms of the biological markers (biomarkers) in their blood between the two states.
Next, Niculescu’s team utilized large databases developed from all previous studies in the field, to cross-validate and prioritize their findings. From here, researchers validated the top 26 candidate biomarkers in independent cohorts of clinically severe people with depression or mania. Last, the biomarkers were tested in additional independent cohorts to determine how strong they were at predicting who is ill, and who will become ill in the future.
From this approach, researchers were then able to demonstrate how to match patients with medications—even finding a new potential medication to treat depression.
“Through this work, we wanted to develop blood tests for depression and for bipolar disorder, to distinguish between the two, and to match people to the right treatments,” said Niculescu. “Blood biomarkers are emerging as important tools in disorders where subjective self-report by an individual, or a clinical impression of a health care professional, are not always reliable. These blood tests can open the door to precise, personalized matching with medications, and objective monitoring of response to treatment.”
In addition to the diagnostic and therapeutic advances discovered in their latest study, Niculescu’s team found that mood disorders are underlined by circadian clock genes—the genes that regulate seasonal, day-night and sleep-wake cycles.
“That explains why some patients get worse with seasonal changes, and the sleep alterations that occur in mood disorders,” said Niculescu.
According to Niculescu, the work done by his team has opened the door for their findings to be translated into clinical practice, as well as help with new drug development.
Focusing on collaboration with pharmaceutical companies and other doctors in a push to start applying some of their tools and discoveries in real-world scenarios, Niculescu said he believes the work being done by his team is vital in improving the quality of life for countless patients.
“Blood biomarkers offer real-world clinical practice advantages. The brain cannot be easily biopsied in live individuals, so we’ve worked hard over the years to identify blood biomarkers for neuropsychiatric disorders,” said Niculescu. “Given the fact that 1 in 4 people will have a clinical mood disorder episode in their lifetime, the need for and importance of efforts such as ours cannot be overstated.”
Original Article: IU School of Medicine researchers develop blood test for depression, bipolar disorder
More from: Indiana University School of Medicine
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Depression
- Merrill Discusses the Association Between Social Media Use, Personality Structure and Depression
Renae Merrill, a doctoral student in the U of A Public Policy Program, discusses the association between social media use, personality structure and depression on the latest Short Talks episode.
- Woman accused of killing her children reportedly had postpartum depression
Clancy, who worked as a labor and delivery nurse, wrote in private Facebook posts viewed by the Boston Globe just weeks after her third child was born that she had struggled with postpartum depression ...
- ‘Baby Ruby’ Review: The Strains of Postpartum Depression Take a Shivery Turn in a Fevered Psychodrama
The strains and vagaries of postpartum depression — still widely misunderstood and even shamed by those who haven’t experienced it — morph into literal horrors in “Baby Ruby,” a stylish and suitably ...
- Can Ketamine alleviate depression from chronic pain?
A research team including a UAB scientist has discovered how chronic pain causes depression and are looking into whether the drug ketamine may be helpful in alleviating it. Dr. Lingyong Li of UAB ...
- Long-term exposure to pollution linked to depression, study finds
An 11-year study in the United Kingdom suggests that long-term exposure to even low levels of pollution is linked to anxiety and other mental health issues.
Go deeper with Google Headlines on:
Depression
[google_news title=”” keyword=”depression” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Bipolar disorder
- Bipolar disorder: Warning symptoms you should know; types, causes, treatment
Bipolar disorder also known as manic depression is a mental health problem characterised by intense highs and lows in a person's mood, energy and ability to function. All you want to know.
- Bipolar Disorder Market is expected to generate a revenue of USD 6.27 Billion by 2030, Globally, at 2% CAGR: Verified Market Research®
The market report is a good combination of qualitative and quantitative data that highlights significant market changes, obstacles that business and the competition must overcome, as well as new ...
- Hearing about bipolar disorder in the news or on social media? Here’s what you should know
Hearing about bipolar disorder in the news and on social media? Mental health experts explain what it is and how it presents in people.
- Detroit police ask for help locating missing 34-year-old man with schizophrenia, bipolar disorder
Police are searching for a Detroit man with schizophrenia and bipolar disorder who failed to return home. According to Detroit police, Demarco Gregory left his house on the 18600 block of Snowden ...
- Bipolar Disorder Treatment Market will achieve USD 5.7 billion by 2030 : GreyViews
These are the key regions where the bipolar disorder treatment market is operating and is predicted to expand soon. The manufacturers and suppliers involved in the bipolar disorder treatment ...
Go deeper with Google Headlines on:
Bipolar disorder
[google_news title=”” keyword=”bipolar disorder” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]